{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:33:39Z","timestamp":1791902019706,"version":"4.3.4"},"reference-count":27,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"25","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Treatment options are limited for patients with recurrent and\/or metastatic (R\/M) cutaneous squamous cell carcinoma (cSCC); mortality rates exceed 70% in patients with distant metastases. Here, we present the first interim analysis of the R\/M cSCC cohort from the 2-cohort\u2014locally advanced and R\/M\u2014phase II KEYNOTE-629 study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>Patients with R\/M cSCC not amenable to surgery or radiation received pembrolizumab 200 mg every 3 weeks. The primary end point was objective response rate per RECIST v1.1. Secondary end points were duration of response, disease control rate, progression-free survival, overall survival, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>At data cutoff (April 8, 2019), median follow-up of 105 enrolled patients in the R\/M cohort was 11.4 months (range, 0.4 to 16.3 months). Objective response rate was 34.3% (95% CI, 25.3% to 44.2%; 4 complete responses, 32 partial responses), and disease control rate was 52.4% (95% CI, 42.4% to 62.2%). Median duration of response was not reached (range, 2.7 to 13.1+ months; \u2018+\u2019 refers to ongoing response at data cutoff). Median progression-free survival was 6.9 months (95% CI, 3.1 months to 8.5 months). Median overall survival was not reached (95% CI, 10.7 months to not reached). Treatment-related adverse events occurred in 66.7% of patients (n = 70), the most common of which were pruritus (n = 15; 14.3%), asthenia (n = 14; 13.3%), and fatigue (n = 13; 12.4%). Grade 3 to 5 treatment-related adverse events occurred in 5.7% (n = 6) of patients. One patient died of treatment-related cranial nerve neuropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Pembrolizumab demonstrated effective antitumor activity; clinically meaningful, durable responses; and acceptable safety in primarily elderly patients with R\/M cSCC, supporting its use in clinical practice. Pembrolizumab adverse events in this study were consistent with its established safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.19.03054","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T15:59:15Z","timestamp":1594915155000},"page":"2916-2925","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":289,"title":["Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)"],"prefix":"10.1200","volume":"38","author":[{"given":"Jean-Jacques","family":"Grob","sequence":"first","affiliation":[{"name":"Aix-Marseille University, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Centro Estatal de Cancerologiade Chihuahua, Chihuahua, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Basset-Seguin","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint-Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Vornicova","sequence":"additional","affiliation":[{"name":"Rambam Health Care Campus, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Schachter","sequence":"additional","affiliation":[{"name":"Chaim Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Joshi","sequence":"additional","affiliation":[{"name":"Townsville University Hospital, Townsville, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Meyer","sequence":"additional","affiliation":[{"name":"Institut Universitaire du Cancer and CHU de Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Grange","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Reims\u2013H\u00f4pital Robert Debre, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Piulats","sequence":"additional","affiliation":[{"name":"Hospital Duran i Reinals L\u2019Institut Catal\u00e0 d'Oncologia de Hospitalet, Idibell, Oncobell, Ciberonc, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"Bauman","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingye","family":"Zhang","sequence":"additional","affiliation":[{"name":"Merck & Co, Kenilworth, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Gumuscu","sequence":"additional","affiliation":[{"name":"Merck & Co, Kenilworth, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona F.","family":"Swaby","sequence":"additional","affiliation":[{"name":"Merck & Co, Kenilworth, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett G. M.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Royal Brisbane and Women\u2019s Hospital, Herston, QLD, Australia"},{"name":"University of Queensland, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1187"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjoms.2014.01.015"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0207-3"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/hed.22913"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/01.MLG.0000158349.64337.ED"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21898"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.06.110"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1768"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2014.08.005"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61196-X"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12728"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805131"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0131-9"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.1524"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31999-8"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.6000"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603702"},{"key":"B21","volume-title":"AACR 106th Annual Meeting","author":"Garon EB"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.2139"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.4994"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23155"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850415)55:8<1629::AID-CNCR2820550802>3.0.CO;2-I"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910415)67:8<2030::AID-CNCR2820670803>3.0.CO;2-K"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.1735"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu368"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.9547"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.19.03054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T05:53:15Z","timestamp":1653803595000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.19.03054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":27,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2020,9,1]]}},"alternative-id":["10.1200\/JCO.19.03054"],"URL":"https:\/\/doi.org\/10.1200\/jco.19.03054","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]},"assertion":[{"value":"2020-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}